Results for Acute Myeloid Leukemia

Dr. Aplenc investigates ways to improve the outcomes of children with cancer, particularly acute myeloid leukemia, with clinical epidemiology studies and translational research.

Dr. Kurre's laboratory has longstanding expertise in Fanconi Anemia (FA), a genetic condition with prominent hematologic complications. With training in transplantation and hematopoietic stem cell biology, he hopes to improve the understanding of the progressive hematopoietic failure in patients with bone marrow failure and FA, broaden diagnostic approaches, and develop next generation therapies.

Dr. Tong investigates cytokine receptor signaling in normal and neoplastic hematopoietic development. She uses integrated approaches encompassing biochemistry, molecular biology, mouse models, and primary human samples to understand signaling events emanating from cytokine receptors that regulate the development of hematopoietic stem/progenitor cells.

Dr. Getz develops and applies advanced methods to enable epidemiologic research that aims to optimize the treatment and supportive care of children with cancer by balancing the therapeutic benefits and toxicity risks with an emphasis in cardio-oncology.

Dr. Tasian's research centers on the bench-to-bedside investigation of precision medicine therapies for high-risk childhood leukemias.

Ding-Wen Chen’s research aims to decipher novel cellular cross talk in the bone marrow microenvironment that promotes disease persistence and recurrence in acute myeloid leukemia.